Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Issa, M.D., Ph.D., FAAD explores the emerging therapies dermatology APPs should be watching in bullous pemphigoid and pemphigus vulgaris, including: Type 2 inflammation and dupilumab B cells and autoantibody production The potential role of JAK-STAT signaling These evolving treatment conversations reflect the immunology-focused clinical education coming to Elevate-Derm Summer 2026
Personalized Plan: If eligible, you receive a treatment plan tailored to your needs
Diabetes 67(Supplement 1):522 Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P et al (2019) Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Uniquely, these two agents from the same company may work as a complementary pair: the ATTAIN-MAINTAIN trial demonstrated that patients can achieve maximum weight loss with injectable tirzepatide and then switch to oral orforglipron for maintenance
Every number in this piece links to the trial, label, or agency notice it came from, so none of it has to be taken on faith
